Free tool
Cell therapy stocks
We cover 20 companies grouped under the Cell therapy theme. The median market value in the group is $498.37M. Across the group, the median move over the past trading day is +4.39%. 75% of the 20 with a 200-day average trade above it. Price change over the past year runs from −27.9% to +145.4% across the middle 80 percent of the group, with a median of +33.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
20 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| BLFS | BioLife Solutions, Inc. | $37.22 | +24.94% | +55.80% | +45.11% | Nov 5, 2026 |
| VOR | Vor Biopharma Inc. | $24.01 | +23.51% | +106.27% | −41.72% | Nov 12, 2026 |
| SANA | Sana Biotechnology, Inc. | $4.10 | +25.00% | −2.15% | +22.39% | Nov 5, 2026 |
| CYRX | Cryoport, Inc. | $16.72 | +10.36% | +74.90% | +89.78% | Nov 3, 2026 |
| ALLO | Allogene Therapeutics, Inc. | $2.17 | +24.00% | +60.74% | +87.07% | Nov 5, 2026 |
| PROK | ProKidney Corp. | $1.73 | +12.34% | −22.42% | −26.38% | Nov 9, 2026 |
| AUTL | Autolus Therapeutics plc | $2.44 | +67.12% | +30.48% | +52.50% | Nov 16, 2026 |
| KYTX | Kyverna Therapeutics, Inc. | $8.84 | +11.62% | +0.80% | +132.02% | Nov 11, 2026 |
| CABA | Cabaletta Bio, Inc. | $3.22 | +18.38% | +45.70% | +102.52% | Nov 16, 2026 |
| 0JDK.L | Iovance Biotherapeutics, Inc. | $8.36 | +1.91% | +222.92% | +248.46% | Nov 5, 2026 |
| 4592.T | SanBio Company Limited | 1,024.00 JPY | +10.58% | −37.45% | −55.90% | Sep 14, 2026 |
| CAPR | Capricor Therapeutics, Inc. | $8.29 | +18.43% | −70.72% | +25.61% | Nov 10, 2026 |
| IPSC | Century Therapeutics, Inc. | $2.17 | +3.83% | +118.09% | +324.66% | Nov 12, 2026 |
| LYEL | Lyell Immunopharma, Inc. | $15.49 | +19.52% | −46.55% | +41.20% | Nov 6, 2026 |
| FATE | Fate Therapeutics, Inc. Common Stock | $2.55 | +4.94% | +157.58% | +133.94% | Nov 12, 2026 |
| RNAC | Cartesian Therapeutics, Inc. | $10.38 | +33.25% | +53.55% | −7.73% | Nov 5, 2026 |
| LCTX | Lineage Cell Therapeutics, Inc. | $1.13 | +9.71% | −31.10% | −3.42% | Nov 5, 2026 |
| NKTX | Nkarta, Inc. | $2.71 | +19.91% | +44.92% | +23.18% | Nov 10, 2026 |
| MXCT | MaxCyte, Inc. | $1.35 | +32.35% | −12.90% | −2.88% | Nov 11, 2026 |
| 0HIY.L | Atara Biotherapeutics, Inc. | $9.92 | +1.60% | −44.67% | −20.36% | Nov 12, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.